Anemia Management in Hemodialysis Patients

Introduction to Anemia Management

The American Journal of Kidney Diseases recommends initiating erythropoiesis-stimulating agent (ESA) therapy with epoetin alfa 50-150 Units/kg intravenously three times weekly for hemodialysis patients with severe anemia, after ensuring adequate iron stores, targeting a hemoglobin of 11-12 g/dL 1, 2

The National Kidney Foundation suggests measuring transferrin saturation (TSAT) and serum ferritin to assess iron stores, targeting TSAT ≥20% and serum ferritin ≥100 ng/mL before starting ESA therapy 1, 2, 3
Administer intravenous iron 100-125 mg per dialysis session for 8-10 consecutive sessions if iron parameters are below target 3
Oral iron is inadequate for hemodialysis patients and unlikely to maintain sufficient iron stores even at 200 mg elemental iron daily 1, 3

The American College of Physicians recommends a starting dose of 50-150 Units/kg IV three times weekly, with a hemoglobin target of 11-12 g/dL 1, 2

The American Society of Nephrology recommends targeting a hemoglobin of 11-12 g/dL, as higher targets (≥13 g/dL) increase cardiovascular mortality and adverse events, while lower targets (<11 g/dL) result in persistent symptoms and increased transfusion requirements 1, 2, 5
Monitor hemoglobin levels weekly during the first 2-3 months of therapy, then monthly once a stable target is achieved 3, 5

If hemoglobin rises appropriately, reduce the dose by 25% when hemoglobin reaches 11 g/dL to prevent overshoot 5
If inadequate response, increase the dose by 25% and reassess iron status (TSAT and ferritin) 2, 3, 5

Continue regular IV iron supplementation during ESA therapy, with 25-125 mg IV iron weekly to maintain TSAT ≥20% and ferritin ≥100 ng/mL 3
Monitor iron parameters every 3 months minimum during maintenance therapy 3

Monitor blood pressure at each dialysis session during ESA initiation and discontinue ESA for refractory hypertension or hypertensive encephalopathy 3, 5
Increase vigilance for arteriovenous fistula thrombosis, particularly during rapid hemoglobin correction 1, 3
Permanently discontinue all ESA therapy if pure red cell aplasia is confirmed 3, 5